A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Phase 2 Completed 20 enrolled Dana-Farber Cancer Institute

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer. These drugs are expected to target the blood vessels that supply the tumors with what they need to grow.

Timeline

Start: 2001-06
Primary completion: 2006-10
Completion: 2006-10

Publications

Results Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005 Nov;27(11):573-81. doi: 10.1097/01.mph.0000183863.10792.d4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	100 mg	Oral
Subject	Cyclophosphamide	Other / unclassified	3.5 mg/m2	Oral
Subject	Etoposide	Small molecule	50 mg/m2	Oral
Subject	Thalidomide	Other / unclassified	3 mg/kg	Oral

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Summary

Timeline

Publications

Drugs

Indications